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Abstract
The presence of hypoxic cells in human brain tumors is
an important factor leading to resistance to radiation
therapy. However, this physiological difference between
normal tissues and tumors also provides the potential
for designing cancer-specific gene therapy. We com-
pared the increase of gene expression under anoxia
( <0.01% oxygen) produced by 3, 6, and 9 copies of
hypoxia-responsive elements (HRE) from the erythro-
poietin gene (Epo ), which are activated through the
transcriptional complex hypoxia - inducible factor 1
(HIF-1). Under anoxic conditions, nine copies of HRE
(9XHRE) yielded 27- to 37- fold of increased gene
expression in U-251 MG and U-87 MG human brain
tumor cell lines. Under the less hypoxic conditions of
0.3% and 1% oxygen, gene activation by 9XHRE
increased expression 11- to 18- fold in these cell lines.
To generate a recombinant adeno-associated virus
(rAAV) in which the transgene can be regulated by
hypoxia, we inserted the DNA fragment containing
9XHRE and the LacZ reporter gene into an AAV vector.
Under anoxic conditions, this vector produced 79- to
110-fold increase in gene expression. We believe this
hypoxia-regulated rAAV vector will provide a useful
delivery vehicle for cancer -specific gene therapy.
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Introduction
Solid tumors are heterogeneous and are composed of
physiologically distinct subpopulations of cells. One impor-
tant feature of human solid tumors is the presence of a
hypoxic microenvironment [1 ]. Pioneering studies by
Thomlinson and Gray [2] demonstrated that hypoxic cells
arose in tumors whenever tumor growth produces cells
that are >150 m from a blood vessel. Clinical studies
using an oxygen electrode to measure the oxygen levels
in patients’ brain tumor tissues have found a significant
number of hypoxic cells in every tumor examined [3].
Hypoxia in solid tumors confers resistance to standard
radiotherapy and chemotherapy [4,5 ]. Furthermore, oxy-
gen-deprived tumor cells are predisposed to a more
malignant phenotype, as characterized by increases in
local invasion, metastatic spread, and genetic instability
[6,7]. Inhibition of cellular proliferation by hypoxia also
may contribute to a resistant phenotype, because current
cancer treatment modalities are primarily effective against
rapidly dividing cells. In brief, hypoxia within tumors most
likely contributes to a poor therapeutic outcome, regard-
less of which cancer treatment is used [7].
In addition to conferring resistance to cancer therapy,
recent clinical and experimental studies have also sug-
gested that the cellular response to hypoxia can result in
dramatic alterations in the expression of a variety of
genes, many of which may lead to more aggressive
phenotypes. For example, hypoxia in solid tumors medi-
ates selection of cells with diminished apoptotic potential
and with genetic alterations such as loss of the p53 tumor
suppressor gene or overexpression of the apoptotic
inhibitor protein Bcl -2 [8 ].
Studies of molecular responses to hypoxia have identified
the major mediator for cellular hypoxic responses as a
transcriptional activator hypoxia- inducible factor 1 (HIF-1)
[9 ]. HIF-1 is a heterodimeric basic helix– loop–helix (bHLH)
protein consisting of two subunits, HIF-1 and HIF-1. HIF-
1 is the unique, O2-regulated subunit that determines HIF-
1 activity [10]. Under hypoxic conditions, HIF-1 binds to the
hypoxia- responsive element (HRE) in the enhancer region
of its target genes and turns on gene transcription. HIF-1
responsive genes include glycolytic and gluconeogenic
enzymes in energy metabolism, vascular endothelial growth
factor (VEGF), transcription factors, glucose transporters,
tyrosine hydroxylase and erythropoietin (Epo), a hormone
that regulates erythropoiesis in accordance with the oxygen-
carrying capacity of the blood. The core consensus sequence
for HRE has been identified as (A/G)CGT(G/C) [11].
Several studies have demonstrated overexpression of
HIF-1 in cancer cells and tissues. For example, increased
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expression of HIF-1 protein has been detected in rat and
human prostate cancer cell lines [12]. Recently, immuno-
histochemical analysis of HIF-1 has revealed increased
expression in a variety of tumor types compared with the
respective normal tissues, including brain, colon, breast,
gastric, lung, skin, ovarian, pancreatic, prostate, and
kidney [13,14]. These results suggest that HIF-1 over-
expression is associated with tumor progression and
invasion, possibly by increased cell growth and metastatic
potential.
Although the presence of hypoxic cells in human brain
tumors is an important factor leading to resistance to cancer
treatments, this physiological difference between normal
tissues and tumors also provides the potential for designing
cancer-specific gene therapy protocols [4 ]. Over the last 10
years a number of viral vectors including adeno-associated
virus (AAV) have been developed to deliver transgenes that
are potentially useful for treating central nervous system
malignancies [15]. However, a fundamental problem for
cancer gene therapy is the lack of tumor specificity; proteins
that are therapeutic in malignant cells also may be harmful to
surrounding normal tissue. One way to circumvent this
problem is to use transcriptionally targeted vectors that can
restrict the expression of the therapeutic proteins primarily to
cancer cells [16].
We have previously demonstrated the feasibility of this
approach by employing a trimer of a minimal (31 bp) HRE
from the human Epo gene to regulate the expression of the
pro-apoptotic BAX gene [17]. In the present study, we
sought to improve the ratio of hypoxic induction of gene
expression. We compared the induction of gene expression
from constructs containing an SV40 minimal promoter and
3X, 6X, or 9XHRE. Our results indicate that 6XHRE
produced a similar increase in gene expression under anoxic
conditions as observed earlier for 3XHRE [17]. However,
9XHRE increased the amount of gene expression markedly
in both cell lines, as compared with the lower HRE copy
numbers. We subsequently characterized induction of gene
expression by 9XHRE under intermediate oxygen concen-
trations. In stable clones transfected with a construct
containing 9XHRE and the suicide gene BAX, gene
expression was increased under hypoxic conditions. Finally,
we report development of a novel recombinant adeno-
associated virus (rAAV) in which the expression of a
transgene is under the control of HREs and occurs only
under hypoxic conditions.
Materials and Methods
Plasmid Construction
Based on the published HRE sequence from the 30
enhancer region of the Epo gene [18], we designed pairs of
oligonucleotides that contain three tandem repeats of the
HRE (G CCC TAC GTG CTG TCT CAC ACA GCG CCT
GTC) [17]. In addition, 6X and 9XHREs were generated by
tandem ligation of the 3XHRE oligonucleotide pairs. These
oligonucleotides were inserted into the multiple cloning sites
of the mammalian expression vector pgal-promoter (Clon-
tech, Palo Alto, CA), which contains an enhancerless SV40
promoter situated upstream of the LacZ gene. The resulting
constructs were named pH3LacZ, pH6LacZ, and pH9LacZ,
respectively (Figure 1 ). To construct pH9BAX, the LacZ
gene in pH9LacZ was deleted using HindIII and NdeI
enzymes and replaced with a murine pro-apoptotic BAX
cDNA fragment flanked by HindIII and NdeI sites. To
construct the plasmid pH9LacZ-AAV, the DNA fragment
containing 9XHRE and the LacZ gene flanked by restriction
enzyme sites SmaI and SalI were inserted into pSSV9
(Figure 1 ). The plasmid pCMVLacZ-AAV was similarly
CMV promoter
Psv40
9XHRE Psv40 LacZ gene
LacZ gene
Figure 1. Structural map of plasmids pH3LacZ, pH6LacZ, pH9LacZ, and rAAV vectors. In pHnLacZ plasmids, the reporter gene LacZ was under the transcriptional
control of different copy numbers of HRE and an SV40 minimal promoter. In pH9LacZ -AAV, the LacZ with nine copies of HRE and the SV40 minimal promoter was
inserted between the two inverted repeat regions ( ITR ). The control vector pCMVLacZ -AAV contains a CMV promoter upstream of the LacZ gene.
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constructed by inserting the CMV promoter and LacZ gene
fragment into pSSV9 (Figure 1 ) [19 ].
Cell Culture
Human glioblastoma cell lines U-251 MG and U-87 MG
and human embryonic kidney cell line 293 were maintained
in complete growth medium (CMEM), which consists of
Eagle’s minimum essential medium (MEM) supplemented
with 1% nonessential amino acids and 10% fetal bovine
serum (FBS). Cultures were incubated in an humidified
atmosphere containing 5% CO2 at 378C.
Induction of Hypoxia in Tumor Cells
Cells were seeded into glass petri dishes, allowed to
attach overnight and then placed into gastight aluminum
gassing jigs. The jigs were subjected to five rounds of
evacuation and flushing with either 95% air and 5% CO2
(oxic conditions) or 95%N2 and 5% CO2 (anoxic conditions)
on a shaking platform at room temperature. We produced
other hypoxic mixtures by using known mixtures of 95% O2/
5% CO2 and 95% N2/5% CO2, which were ordered from the
manufacturer (Nellcor Puritan Bennett, Pleasanton, CA).
After the last round of gas exchange, the jigs were placed in a
378C incubator and incubated for 16 hours.
Transient Transfection
Cells (4105) were plated into 6-cm glass petri dishes
and grown for 16 to 18 hours until cell growth reached log
phase and cell density was 50% confluent. Multiple sets of
dishes in either duplicate or triplicate were prepared for each
plasmid sample. Transfections were performed using 6 l of
lipofectamine (2 mg/ml, Gibco BRL Life Technologies,
Gaithersburg, MD), 5 g of plasmid containing LacZ and
various copy number of HREs, and 0.5 g of DNA containing
the luciferase reporter gene ( to correct for transfection
efficiency) in 2 ml of serum-free CMEM for 5.5 hours. Then,
the transfection solution in each dish was replaced with 4 ml
of fresh CMEM and incubated at 378C for 24 hours. One set
of dishes was grown under normal oxic conditions and the
other sets were subjected to different hypoxic conditions for
16 hours. Cells were then harvested and assayed for  -
galactosidase ( -gal ) activity by the enzymatic method
described below.
Stable Transfection
Cells were stably transfected with pH9BAX using lipofect-
amine reagent. For U-251 MG, 2105 cells /well were
transfected with 5 g of DNA and 7.5 l of lipofectamine.
Thirty -six hours after addition of the DNA and lipofectamine,
growth medium was changed and cells were incubated in
growth medium containing 600 g/ml G418 (Gibco BRL Life
Technologies) to select for stably transfected clones. Growth
medium was replaced with fresh medium containing G418
every 2 to 3 days to maintain the concentration of active
G418. After 10 to 12 days of G418 selection, individual
surviving clones were isolated and expanded in six-well
dishes. Stably transfected clones were maintained in
medium containing 600 g/ml G418.
rAAV Production
rAAV was produced by using the three-plasmid cotrans-
fection system as described previously [20]. Briefly, human
embryonic kidney 293 cells were grown in MEM containing
10% FBS in 15-cm plastic petri dishes to 70% confluence.
To generate AAVH9LacZ virus, the cells were cotransfected
with 17 g of plasmid pH9LacZ-AAV per dish along with 17
g of plasmid pHLP19 and 17 g of plasmid pLadeno5 per
dish. pHLP19 has AAV rep and cap genes, which provide the
trans functions of rAAV. pLadeno5 has the adenoviral VA,
E2A and E4 regions that mediate rAAV replication. To
generate AAVCMVLacZ virus, plasmid pCMVLacZ-AAV
was used in place of pH9LacZ-AAV in the above cotrans-
fection process. The medium was changed after 16 hours to
CMEM. After an additional 24 hours, the cells were collected
and lysed by three freeze–thaw cycles. Viral supernatants
were generated by centrifugation at 10,000g for 5 minutes
and further purified by CsCl -gradient ultracentrifugation; the
titer for each rAAV was determined by dot blot assay. This
assay provides a titer of total number of particles per unit
volume. The supernatant containing rAAV was stored in
aliquots at 808C and thawed for use immediately before
each experiment.
rAAV Infection
U-251 MG cells were grown to 70% confluence in 6-cm
glass petri dishes. For infection, the growth medium was
replaced with rAAV-containing medium and dishes were
incubated for 48 hours at 378C in 5% CO2. At the end of the
incubation period, cells were subjected to  -gal expression
analysis using either an enzymatic assay or an X-gal in situ
staining assay.
Western Immunoblotting
Total cellular protein was extracted from cell lines by
lysing cells in 0.5 ml of phosphate-buffered saline (PBS)
containing 0.5% deoxycholate, 1% Nonidet P-40 and 0.1%
sodium dodecylsulfate (SDS) at pH 7.4. To reduce sample
viscosity, DNA was sheared by passage through an 18-
gauge needle. Samples were boiled for 3 minutes, immedi-
ately cooled on ice, and spun for 5 minutes at 10,000 rpm in a
microcentrifuge to remove insoluble material. Supernatants
were assayed for protein concentration using the Bradford
method [21] (Bio-Rad, Hercules, CA) and then stored at
708C. Before electrophoresis, sample buffer containing
bromophenol blue was added to reach a final concentration
of 10% glycerol, 2% SDS, and 50 mM Tris–Cl, pH 6.8.
Protein samples were boiled for 3 minutes and cooled before
loading. Equal amounts of total protein were separated on an
SDS–polyacrylamide gel for 1.5 hours at 150 V using a Bio-
Rad minigel apparatus (Bio-Rad). The protein gel was
transferred to a polyvinylidene difluoride membrane (Amer-
sham, Buckinghamshire, UK) for 1 hour at 100 V in transfer
buffer containing 25 mM Tris–HCl, 40 mM glycine, and 20%
methanol at pH 8.3. The membrane was stained for total
protein using Ponceau-S (Sigma, St. Louis, MO). Mem-
brane was blocked with PBS containing 5% skim milk
powder and 0.05% Tween 20 at pH 7.4. After incubation for 1
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hour at room temperature, fresh blocking solution containing
either the anti -human HIF-1 antibody (Novus Biologicals,
Littleton, CO) or the anti -murine BAX antibody (Genzyme,
Cambridge, MA) was added and the membrane was
incubated for 1 hour. The membrane was washed three
times in PBS containing 0.05% Tween 20 at room temper-
ature and followed by incubation with a peroxidase- labeled
secondary antibody (Jackson ImmunoResearch Laborato-
ries, West Grove, PA) for 1 hour at room temperature. After
three washes in PBS plus 0.05% Tween 20, the membrane
was incubated for 1 minute in enhanced chemiluminescence
buffer (Amersham) and proteins were visualized on an X-
ray film using exposure times varying from 30 seconds to 5
minutes.
 -gal and Luciferase Assays
Transfected cells were washed with PBS, removed from
the glass surface using a rubber policeman and transferred
into Eppendorf tubes. Cells were lysed using the ‘‘freeze–
thaw’’ method, centrifuged, and the supernatants were
collected. The supernatants were assayed for  -gal activity
using a chemiluminescent method according to the manu-
facturer’s directions (Clontech). Briefly, an aliquot of super-
natant was incubated with substrate at room temperature for
1 hour and the light intensity was measured using a Model
20e luminometer (Turner Designs, Sunnyvale, CA). The
cotransfected luciferase activity of the extract was deter-
mined using a kit from Promega (Madison, WI). An aliquot of
the supernatant was incubated with the luciferase substrate
luciferin, and the light intensity emitted by the sample was
measured using the luminometer.  -Gal activity was
normalized to the cotransfected luciferase activity to stand-
ardize the efficiency of transient transfections. In some
transfections,  -gal activity was normalized to cellular
protein level, which was measured using the Bradford
method [21].
X-gal In Situ Staining
Cells were fixed in 0.2% glutaraldehyde and 2% paraf-
ormaldehyde for 5 minutes, and washed twice with PBS. The
cells were immersed in a staining solution containing 100
mM sodium phosphate (pH 7.3), 1.3 mM MgCl2, 3 mM
K3Fe(CN)6, 3 mM K4Fe(CN)6, and 5-bromo-4-chloro-3-
indolyl - -D-galactoside (X-gal, 1 mg/ml) and incubated at
378C for 18 hours. The stained cells were washed twice with
PBS and examined under a light microscope.
Results
Induction of HIF-1 Expression under Anoxic Conditions in
Glioblastoma Cell Lines
To determine whether HIF-1 expression was induced
under anoxic conditions, we analyzed HIF-1 levels under
both oxic and anoxic conditions in two glioblastoma cell lines
using Western blots. After exposure to either oxic or anoxic
conditions for 16 hours, cells were harvested and total
protein was extracted from these cells. Equal amounts (25
g) of protein were analyzed by 7% SDS–polyacrylamide
gel and immunoblotting was performed using a monoclonal
anti -human HIF-1 antibody. U-87 MG cells showed
minimal expression of HIF-1 under oxia and a strong
signal under anoxia; by densitometry measurement there
was about a 15- fold increase in gene expression under
anoxia (Figure 2 ). In U-251 MG cells, HIF-1 showed
strong expression under oxia, and anoxia exposure
increased expression only mildly (1.4- fold) (Figure 2 ).
Effect of HRE Copy Number on Anoxia- Induced Gene
Expression
More than a dozen hypoxia- regulated genes have been
identified as containing HREs in their flanking regions [9]. In
our study, we have used an HRE derived from the human
Epo 30 flanking region in its natural context. To investigate
the influence of HRE copy number on the induction ratio of
hypoxic to oxic heterologous gene expression in these cells,
3X, 6X, and 9XHRE were inserted adjacent to an SV40
minimal promoter in a mammalian expression vector that
contained the LacZ gene (Figure 1 ). We have previously
compared pH3LacZ gene expression under both oxic and
anoxic conditions in U-251 MG and U-87 MG cells [17]. In
the present paper, we first asked whether increasing HRE
copy number from 3 to 6 or 9 would affect gene expression
under oxic conditions. We transiently transfected these
plasmids into U-87 MG and U-251 MG human glioblastoma
cells using the lipofectamine-mediated method. To correct
for variation in the efficiencies of transfection, we included in
the DNA/ liposome complex a control plasmid containing the
luciferase reporter gene. Forty hours after transfection, we
collected protein extracts from transfected cells and assayed
them for  -gal activity, which was normalized by the
cotransfected luciferase activity. As shown in Table 1, for
U-251 MG cells, increasing HRE copy number above 3
resulted in very similar basal gene expression under oxic
conditions. For U-87 MG cells, basal gene expression
Figure 2. Cell type–specific induction of HIF -1 under anoxic conditions.
After exposure to either oxic or anoxic conditions for 16 hours, U -87 MG and
U-251 MG cells were harvested and lysed. Equal amounts (25 g ) of proteins
were analyzed by 7% SDS -PAGE and immunoblotting was performed using a
monoclonal anti - human HIF -1 antibody (Novus Biologicals ). U -87 MG
cells showed minimal expression of HIF - 1 under oxia and significantly
increased HIF -1 under anoxia. In contrast, in U -251 MG cells HIF - 1
showed considerable expression under oxic conditions and increased only
slightly under anoxic conditions.
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remained similar for 3X and 6XHRE, however, for 9XHRE
the average basal gene expression was about two- fold
higher than for either 3X or 6XHRE (Table 1).
This increase in basal gene expression under oxic
conditions, however, was very small compared to that
observed under anoxic conditions. To measure this, we
transiently transfected the plasmids into U-251 MG and U-
87 MG cells. Twenty- four hours after transfection, cells were
made anoxic for 16 hours. At the end of the anoxic period, we
collected protein extracts from transfected cells and assayed
them for  -gal activity. The  -gal activity in cells that were
maintained under oxic conditions served as a control. In U-
251 MG cells, 3XHRE increased gene expression about
four- fold under anoxia (Figure 3 ), consistent with our
previous findings [17]. Expanding HRE copy number to 6
did not further increase gene expression compared with
3XHRE. However, when HRE copy number was increased to
9, we observed that gene expression increased to 27- fold.
We observed similar patterns of induced gene expression in
U-87 MG cells; both 3X and 6XHRE produced about a 13-
fold increase in gene expression, whereas 9XHRE further
increased gene expression to 37- fold (Figure 3 ).
Effect of 9XHRE on Gene Expression under Intermediate
Oxygen Concentrations
Because many hypoxic tumor cells exist under intermedi-
ate oxygen levels [22], a successful hypoxia- targeted gene
Table 1. Gene Expression in Oxic Cells Exposed to Gene Constructs
Containing LacZ under the Control of 3X, 6X, and 9XHREs.
Plasmid Normalized  - gal Activity ( relative light units /g )*
U -251 MG U-87 MG
pH3LacZ 23.3±7.0 28.7±5.1
pH6LacZ 29.9±2.0 22.3±3.7
pH9LacZ 28.8±2.8 45.2±8.5
*Numbers with errors in the table are the means and standard deviations of
three independent samples.
Figure 3. Anoxia - induced LacZ expression depends on HRE copy number.
U -87 MG and U-251 MG cells were transiently transfected with plasmids
containing the LacZ reporter gene and 3X, 6X, and 9XHRE. Transfected cells
were incubated under either anoxic or oxic conditions for 16 hours before
analysis for LacZ activity. The relative level of LacZ expression in oxic cells
was designated as 1.0. The actual values obtained from two independent
experiments are shown for U -87 MG cells ( – – , –!– ) and U-251 MG
cells ( – – , –r– ).
Figure 4. Differential regulation of LacZ expression in pH9LacZ under
intermediate oxygen concentrations. U -87 MG and U-251 MG cells were
transiently transfected with the plasmid containing LacZ reporter gene and
9XHRE. Transfected cells were incubated under different oxygen concen-
trations for 16 hours before analysis for LacZ activity. The relative level of
LacZ expression in oxic cells was designated as 1.0. The actual values
obtained from two independent experiments are shown for U -87 MG cells
( – – , –!– ) and U-251 MG cells ( – – , –r– ).
Figure 5. Western blot showing BAX expression under Oxic (O ) and Anoxic
(A ) conditions in pH9BAX–stably transfected U -251 MG clones. The
intensity of the BAX protein was quantified using densitometry; the fold
increase in BAX expression under anoxic conditions ranged from 10 to 39.
o
o 
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therapy will need to be functional under a range of hypoxic
conditions. Therefore, we determined whether 9XHRE could
increase gene expression under two intermediate levels of
hypoxia. For these studies, we transiently transfected
pH9LacZ into both U-87 MG and U-251 MG cells. Trans-
fected cells were then incubated under 1% oxygen, 0.3%
oxygen or anoxic conditions. After a 16-hour incubation
period, cells were harvested and  -gal activities were
assayed. Compared to oxic conditions, gene expression in
U-251 MG cells increased 11- and 14- fold under 1% and
0.3% oxygen, respectively, whereas the fold increase under
anoxia was 25 (Figure 4 ). Similarly, gene expression in U-
87 MG cells increased 16- and 18- fold under 1% and 0.3%
oxygen, respectively (Figure 4 ), whereas the fold increase
under anoxia was 38.
Evaluation of an HRE Vector that Expressed BAX Under
Hypoxia
We demonstrated previously that overexpression of the
pro-apoptotic BAX gene can kill anoxic tumor cells [17],
indicating BAX might be a potentially useful suicide gene in
hypoxia- targeted gene therapy. To determine whether the
9XHRE vector system could be employed to specifically
express a suicide gene under hypoxic conditions, we
generated pH9BAX. We then transfected this plasmid into
U-251 MG cells and selected for stably transfected clones.
Five clones were analyzed for BAX expression under both
oxic and anoxic conditions using the Western blot method.
As shown in Figure 5, under oxic conditions there was no
detectable BAX expression in all five clones, indicating the
9XHRE regulatory system displayed minimal promoter
leakage. When these clones were incubated under anoxic
conditions for 16 hours, however, BAX expression was
significantly upregulated in all clones. Densitometric scan-
ning of the Western blots indicated that BAX expression
increased from 10- to 39- fold, compared with the minimal
expression measured under oxic conditions.
Hypoxic Induction in Glioblastoma Cells Infected with
AAVH9LacZ Virus
To examine the magnitude of hypoxic induction in cells
infected with the AAVH9LacZ virus, exponentially growing
U-251 MG cells were infected with the recombinant virus.
One day after infection, we incubated cells under anoxic or
oxic conditions for 16 hours and then measured the levels of
Table 2. Infection of U -251 MG Cells by the recombinant AAV, AAVH9LacZ*.
Experiment Normalized  - gal Activityy
( relative light units /g )
Fold of Increase
(Anoxic /Oxic )
Oxic
1 56.0±2.7
2 76.7±15.5
Anoxic
1 6140±786 110
2 6055±548 79
*Multiplicity of infection (MOI)=25.
yNumbers with errors in the table are the means and standard deviations of
four independent samples.
Figure 6.  - gal expression in U -251 MG cells. U -251 MG cells ( 3105 ) were infected with either AAVH9LacZ or AAVCMVLacZ at an MOI of 25 and incubated
under either oxic or anoxic condition for 16 hours. At the end of incubation, cells were assayed for  - gal expression by the X -gal in situ staining method as described
in the Materials and Methods section.
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 -gal quantitatively using a chemiluminescent assay. Sig-
nificant increases of  -gal were detected in the anoxic cells
compared with the oxic cells. As shown in Table 2, anoxic
incubation gave 79- to 110- fold increase in gene expression
compared with oxic conditions in two independent experi-
ments. In addition, we found that the absolute level of gene
expression from 9XHRE/Psv40 promoter was about 70% of
that from the strong constitutive CMV promoter under anoxic
conditions. Infected U-251 MG cells were also stained for  -
gal expression using the X-gal in situ staining method. As
shown in Figure 6,  -gal expression was minimal when cells
were incubated under oxic conditions. However, anoxic
incubation led to a significant increase in  -gal expression.
As a control,  -gal expression from AAVCMVLacZ virus
showed strong expression under both oxic and anoxic
conditions.
Discussion
Hypoxia is a well - recognized feature of human brain
tumors and is an important factor in tumor angiogenesis,
invasion, and malignant growth [13]. A recent clinical study
by Rampling and colleagues [3] made multiple measure-
ments of pO2 at various locations in primary and metastatic
brain tumors. The mean pO2 in tumors ranged from 0.01%
to 3.2%, and the percentage of measurements that were
<0.3% in each of these tumors ranged from 9.5 to 68.5%.
Solid tumors cannot grow beyond a volume of several cubic
millimeters in the absence of vascularization, and there is
an inverse relation between tumor hypoxia and patient
survival [9]. Overall, both basic and clinical studies have
pointed out that tumor hypoxia is a significant problem for
tumor resistance to radiotherapy and chemotherapy [4].
Our goal is to develop a gene therapy strategy to
specifically kill hypoxic tumor cells. In combination with
radiation therapy, which can efficiently kill well -oxygenated
cells, this gene therapy approach should improve the
therapeutic outcome for brain tumor patients.
HIF-1 is the master regulator of hypoxia- inducible gene
expression and increased expression of HIF-1 protein has
been detected in cancer cells. In this study, we first
measured the expression of HIF-1 in two human glioblas-
toma cell lines. We found that HIF-1 protein in U-87 MG
cells was minimal under oxic conditions but increased
significantly when cells were incubated for 16 hours under
anoxic conditions. In contrast, HIF-1 protein in U-251 MG
cells was detected under both oxic and anoxic conditions,
with only a slight increase in response to anoxic exposure.
However, the absolute levels of gene expression under oxic
conditions as measured by  -gal activities were essentially
equivalent in both cell lines. We postulate that U-251 MG
cells may have developed mechanisms to suppress activity
of HIF-1 and render it nonfunctional under oxic conditions. It
will be interesting to compare the expression levels of HIF-1
target genes such as VEGF between these two cell lines.
These two cell lines are also heterogeneous with respect to
other biologic properties. For example, these cells exhibit
different sensitivities to anoxia; exposure of U-87 MG cells
for 16 hours kills50% of the cells, whereas very few U-251
MG cells are killed under these conditions (Ruan and
colleagues, unpublished data). Furthermore, it is known that
U-87 MG cells carry a wild- type p53 gene, whereas p53 in
U-251 MG cells is mutated [23]. Loss of wild- type p53
function in tumor cells has been implicated in enhancing
HIF-1 levels in response to hypoxia [24]. Our data support
the notion that the mutated p53 gene in U-251 MG cells
might result in increased expression of HIF-1 even under
oxic conditions.
Several studies by others indicate that the hypoxic
environment can be used to activate heterologous gene
expression driven by HRE. For example, Dachs and
colleagues [25] showed that an HRE from the mouse
phosphoglycerate kinase-1 gene could be used to control
expression of marker and the therapeutic genes in vitro and
within a solid tumor in vivo. In another study, Shibata and
colleagues [26] have developed a hypoxia- responsive
vector containing 5XHRE derived from the human VEGF
gene combined with a CMV minimal promoter. Cells trans-
fected with the vector exhibited over 500- fold increased
transgene expression under hypoxia, similar to the level of
the intact CMV promoter.
The amount of induced gene expression required to
achieve selective tumor cell killing under hypoxia needs to be
empirically determined for any given experimental system.
Too low a ratio will not kill enough tumor cells, whereas too
high a ratio may cause an adverse effect on surrounding
normal cells. Therefore, in this study we investigated how
increased gene expression under hypoxic conditions
depends upon the HRE copy number. We chose the 31-bp
human Epo HRE sequence for this study, and we inves-
tigated the hypoxia- induction ratio in plasmids containing
3X, 6X, and 9XHRE. Our results indicate that 9XHRE
constructs produced the highest level of gene expression in
both human glioblastoma cell lines studied. It remains to be
determined whether increasing HRE copy number beyond 9
will further increase the hypoxia- induction ratio.
In our model systems, HRE copy number is an
important component in the regulation of hypoxia- induced
gene expression. Our data also indicate that the SV40
minimal promoter is a suitable basal promoter to be used
in combination with HRE enhancers, because increased
gene expression occurred under hypoxic conditions with-
out any important increase in gene expression under oxic
conditions ( i.e., leakage). Boast and colleagues [27] also
found that the SV40 minimal promoter and 3XHRE from
the polyglycerate kinase gene gave a 146- fold induction
of gene expression under hypoxia without increased basal
level expression.
Because we wish to develop a therapy that kills tumor
cells under hypoxic conditions, we have tested hypoxic
induction of the suicide gene BAX. BAX is a member of the
Bcl -2 protein family and overexpression of BAX causes
apoptosis in both cell cultures and animals [28]. We have
recently analyzed BAX expression in U-251 MG clones
stably transfected with the construct containing 3XHRE and
BAX [29]. Our results suggested that 3XHRE may be
Neoplasia . Vol. 3, No. 3, 2001
Hypoxia-Regulated Gene Expression Ruan et al. 261
insufficient to increase BAX expression under hypoxia in
these clones. Because gene induction under hypoxia in the
context of 9XHRE is significantly higher than that in 3XHRE,
we decided to generate stable U-251 MG clones transfected
with pH9BAX and examine hypoxic induction of BAX
expression. There was minimal or undetectable BAX
expression under oxic conditions in all clones, indicating no
promoter leakage. Under anoxic conditions, we observed
strong induction of BAX expression, ranging from 10- to 39-
fold. Although we do not yet know howmuch increase in BAX
gene expression is needed to kill hypoxic cells, studies on
other therapeutic genes, such as cytosine deaminase and
HSV-thymidine kinase genes, have found that only an
approximately two- to seven- fold increase in gene expres-
sion was sufficient for hypoxic cell killing [25,30]. The
magnitude of BAX expression needed to kill hypoxic cells in
each of our model systems will have to be determined
empirically.
Because it is unlikely that all tumor cells in vivo can be
transfected with the suicide gene, the bystander effect will
need to play a prominent role in successful gene therapy
[31]. The development of the stably transfected pH9BAX
clones will allow us to study any bystander effect that may be
elicited by BAX. Ideally, the bystander effect will occur
primarily in tumor cells and have limited effect on adjacent
normal cells. It will be necessary to determine what the
optimal level of BAX induction is to achieve such a beneficial
bystander effect.
To exploit hypoxia- targeted gene therapy using an HRE-
regulated system, it will be important to use an effective
delivery system. Recently, an adenoviral vector, in which the
transgene was under transcriptional control of HRE, pro-
duced inducible gene expression in response to hypoxia in a
range of cell lines [32]. However, there are problems
associated with adenovirus that could hamper its potential
application for gene therapy in humans. These include the
host immune reaction and inflammatory response elicited by
viral genes and the reported toxicity of adenovirus to human
tissues such as liver [33]. We decided to use an AAV vector
system, because in the rAAV vector, both viral genes are
removed and replaced with the desired therapeutic gene.
Therefore, the risk of immune reaction is minimized because
the vector cannot code for its own gene products [34]. Also,
AAV is efficient in delivering its gene to both dividing and
nondividing cells. This capability is important for the type of
gene therapy that we propose, because most hypoxic cells
are expected to be quiescent.
Finally, it will be critical that the AAV vector be able to
reach tumor cells and it has to be minimally toxic to the
surrounding normal brain tissue. The broad tropism of AAV
makes targeting gene expression particularly important, and
the goal for a targeted gene delivery system is to achieve low
basal activity with high inducible expression levels. For
example, hepatocarcinoma-specific expression of a thera-
peutic gene in rAAV has been demonstrated by employing
the  - fetoprotein enhancer and albumin promoter;  -
fetoprotein is expressed in most hepatocarcinomas with no
detectable levels in normal adult liver tissue [35]. These
tumor-specific parameters were also achieved in our rAAV,
AAVH9LacZ, through the regulation of hypoxic conditions.
When we inserted the DNA fragment containing 9XHRE and
LacZ into the AAV vector, the resulting rAAV could be
specifically regulated by hypoxia. LacZ expression was 79-
and 110- fold higher under anoxic conditions compared to
oxic conditions in U-251 MG human glioblastoma cells. X-
gal in situ staining experiments also confirmed increased
gene expression in AAVH9LacZ- infected U-251 MG cells
under anoxic conditions. Furthermore, the activity of the
9XHRE/Psv40 promoter is comparable with that of CMV
promoter under anoxic conditions, indicating this promoter
can lead to strong expression of the target gene. Similar
HRE-regulated systems have been described previously.
When an expression cassette containing 3XHRE derived
from the human phosphoglycerate kinase gene linked with
the SV40 minimal promoter was configured into an adeno-
viral vector, a range of cell types displayed low basal
transgene expression and highly inducible level under
hypoxia [32].
In summary, we have developed a novel rAAV in which
transgene expression was specifically regulated by hypoxia,
resulting in strong induction under hypoxic conditions. We
believe this hypoxia- regulated rAAV vector will provide a
useful delivery vehicle for tumor- targeted gene therapy, and
we plan to test this hypothesis in vivo.
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